RecruitingNCT06353087

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib

Sponsor

Pfizer

Enrollment

200 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

Dermatitis Eczema Immune System Diseases Skin Diseases Dermatitis Atopic Janus Kinase Inhibitors

Summary

This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with dermatitis, dermatitis atopic, and other related conditions. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.